Pharmafile Logo

Event: World Pharma Pricing and Market Access Congress

May 2, 2019 | Pharma, healthcare 

Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March.

This two-day event was attended by over 600 delegates, including a number of payers from Europe, the US and Latin America, plus representatives from the industry and other market access organizations. In the morning plenary sessions, we heard a range of perspectives on value, demonstrating that “value is in the eye of the beholder”. A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy. There was much discussion about how these products, with their high upfront costs and inherent limitations will necessitate the creation of a new access model. To allow negotiations to move forward and ensure more timely access to patients, we need to look at using innovative payment models such as outcomes-based contracting and find ways of addressing uncertainty.

Find out more about their time at the event.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Eyeforpharma Real World Evidence Conference Round up 2018

Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)This year has seen a turning point...

EphMRA Annual Conference 2018

Visit us on stand number 20

Connected Patients – Adopting a patient-centric approach in emerging markets

The concept of patient centricity and putting the patient at the heart of care is being widely adopted by the healthcare industry – the general consensus being that it’s going...

Combination therapies in oncology: The benefits of integrated insights

14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE

Intellus round up 2018

Earlier this month, US President Harriet Kozak and Emerging Markets Director Rachel Howard attended the inaugural Intellus Worldwide Summit in Philadelphia

Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research...

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

How integrated insights supported a biologic launch strategy across multiple indications

Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their...

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...